Biotech News - Biotech eyes RTP location - United Therapeutics
Biotech News - Biotech eyes RTP location
Biotech eyes RTP location
Amanda Jones
RESEARCH TRIANGLE PARK - North Carolina lost the battle to Maryland last year for United Therapeutics' $32 million lab facility, but the woman-led biotechnology company is looking at the Triangle again for a $50 million project.
United, which is based in Silver Spring, Md., wants to build a 200,000-square-foot manufacturing and laboratory building in Research Triangle Park that could employ as many as 300 workers.
Roger Jeffs, United's president and chief operating officer, says the company's current focus is on building sites in RTP, and United has been working with state, Wake County and RTP economic developers for a suitable location. "We hope to finalize the decision on the selection of an appropriate site in the coming months," says Jeffs, who is based in RTP. United Chairwoman and CEO Martine Rothblatt works out of the firm's Maryland office.
Jeffs hinted that the company is looking at some other sites outside of RTP. He said the facility will manufacture and package the oral tablet form of the company's lead drug, Remodulin. The research and development group and related sales and marketing teams associated with the drug would be housed in the same facility. The tablet form of Remodulin has yet to be approved by the FDA.
Biotech eyes RTP location
Amanda Jones
RESEARCH TRIANGLE PARK - North Carolina lost the battle to Maryland last year for United Therapeutics' $32 million lab facility, but the woman-led biotechnology company is looking at the Triangle again for a $50 million project.
United, which is based in Silver Spring, Md., wants to build a 200,000-square-foot manufacturing and laboratory building in Research Triangle Park that could employ as many as 300 workers.
Roger Jeffs, United's president and chief operating officer, says the company's current focus is on building sites in RTP, and United has been working with state, Wake County and RTP economic developers for a suitable location. "We hope to finalize the decision on the selection of an appropriate site in the coming months," says Jeffs, who is based in RTP. United Chairwoman and CEO Martine Rothblatt works out of the firm's Maryland office.
Jeffs hinted that the company is looking at some other sites outside of RTP. He said the facility will manufacture and package the oral tablet form of the company's lead drug, Remodulin. The research and development group and related sales and marketing teams associated with the drug would be housed in the same facility. The tablet form of Remodulin has yet to be approved by the FDA.
posted by Famous Quotations - Biotech News - Biotech eyes RTP location - United Therapeutics
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home